z-logo
Premium
Zebrafish larvae as a model to demonstrate secondary iron overload
Author(s) -
Nasrallah Gheyath K.,
Younes Nadin N.,
Baji Missbah H.,
Shraim Amjad M.,
Mustafa Ibrahim
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13035
Subject(s) - deferoxamine , hemoglobin , ferric , zebrafish , anemia , chelation therapy , colorimetry , chelation , chemistry , pharmacology , biochemistry , medicine , chromatography , inorganic chemistry , gene
Objectives Thalassemia is the most common genetically inherited blood disorder arising from a defect in hemoglobin production, resulting in ineffective erythropoiesis and severe hemolytic anemia. While transfusion therapy corrects the anemia, it gives rise to secondary iron overload. Current iron chelation therapy performed using deferoxamine, and the efficiency of this drug was demonstrated here using the zebrafish animal model. Methods Zebrafish larvae were exposed for 3 days to iron [100 μmol L −1 ferric ammonium citrate; 3‐6 days post fertilization (dpf)]. Then, iron treated larvae were exposed to 100 μmol L −1 deferoxamine for 3 days (6‐9 dpf). Total tissue iron concentration in the whole larvae, assessed by three different assays; inductively coupled plasma mass spectrometry, colorimetry (spectrophotometry), and microscopy using iron staining followed by imaging and quantification. Results The three assays showed that iron treatment alone resulted in a significant increase in total iron. Deferoxamine treatment of the iron‐loaded zebrafish larvae showed a significant decrease in total iron concentration. Conclusion This study presented a clear evidence of the effectiveness of zebrafish larvae to use as a tool to study iron overload and open the door for studying the efficiency of potential new iron chelating compounds other than commercially available ones.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here